Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CASP6 | P55212 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5455141 | 0.81 | CA12 (0.39) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL5461338 | 0.79 | CA12 (0.40) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL8683462 | 0.77 | CA12 (0.39) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL4700076 | 0.75 | CA12 (0.37) | CA12CA1CA2CA9MEN1 | |
| SCHEMBL6674365 | 0.73 | CRHBP (0.39) | CRHBPCRHR2KEAP1NFE2L2TSHR | |
| SCHEMBL14428389 | 0.69 | SIGMAR1 (0.36) | CA12CA1CA2CA9 | |
| SCHEMBL6365684 | 0.69 | ATM (0.37) | CA12CA1CA2CA9CRHBP | |
| SCHEMBL15008834 | 0.68 | CA12 (0.39) | CA12CA1CA2CA9 | |
| SCHEMBL6679523 | 0.68 | KDM4E (0.38) | CRHBPCRHR2KEAP1NFE2L2TSHR | |
| SCHEMBL6674064 | 0.67 | TSHR (0.45) | CRHBPCRHR2KEAP1NFE2L2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2007-08-16 | — | — | US | claimed |
| EP-1044005-A4 | 1,2,4-BENZOTRIAZINE OXIDES FORMULATIONS | SANOFI SYNTHELABO INC (US) | 2001-08-08 | — | — | EP | claimed |
| US-6153610-A | 1,2,4-benzotriazine oxides formulations | SANOFI-SYNTHELABO INC. (US) | 2000-11-28 | — | — | US | claimed |
| EP-1044005-A1 | 1,2,4-BENZOTRIAZINE OXIDES FORMULATIONS | Sanofi-Synthelabo, Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| WO-1998047512-A1 | 1,2,4-BENZOTRIAZINE OXIDES FORMULATIONS | SANOFI PHARMACEUTICALS, INC. (US) | 1998-10-29 | — | — | WO | claimed |
| US-5827850-A | INJECTING IN BUFFERED AQUEOUS SOLUTIONS; ANTITUMOR OR ANTICARCINOGENIC AGENTS | SANOFI PHARMACEUTICALS, INC. (US) | 1998-10-27 | — | — | US | claimed |
| US-7816521-B2 | 1,2,4-benzotriazine-1,4-dioxides | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-10-19 | — | — | US | disclosed |
| US-20070197534-A1 | Novel 1,2,4-benzotriazine-1,4-dioxides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-08-23 | — | — | US | disclosed |
| EP-1044005-B1 | 1,2,4-BENZOTRIAZINE OXIDES FORMULATIONS | SANOFI SYNTHELABO INC (US) | 2006-07-05 | — | — | EP | disclosed |
| EP-1044005-A4 | 1,2,4-BENZOTRIAZINE OXIDES FORMULATIONS | SANOFI SYNTHELABO INC (US) | 2001-08-08 | — | — | EP | disclosed |
| US-6153610-A | 1,2,4-benzotriazine oxides formulations | SANOFI-SYNTHELABO INC. (US) | 2000-11-28 | — | — | US | disclosed |
| EP-1044005-A1 | 1,2,4-BENZOTRIAZINE OXIDES FORMULATIONS | Sanofi-Synthelabo, Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1998047512-A1 | 1,2,4-BENZOTRIAZINE OXIDES FORMULATIONS | SANOFI PHARMACEUTICALS, INC. (US) | 1998-10-29 | — | — | WO | disclosed |
| US-5827850-A | INJECTING IN BUFFERED AQUEOUS SOLUTIONS; ANTITUMOR OR ANTICARCINOGENIC AGENTS | SANOFI PHARMACEUTICALS, INC. (US) | 1998-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191372-A1 | Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy | HIF1AN, HIF1A, HYOU1 | CA12 1186/4885CA1 661/4885CA2 21/4885 |
| US-20070197534-A1 | Novel 1,2,4-benzotriazine-1,4-dioxides | HIF1AN, HIF1A, HYOU1 | CA12 871/4885CA1 261/4885CA2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.